Breast cancer survivors find relief for debilitating menopause symptomBreast cancer survivors find relief for debilitating menopause symptom
About 50% of menopausal women experience genitourinary syndrome of menopause (GSM) that involves changes to the genitals, including the vagina, urethra and bladder. When estrogen levels drop during menopause, it can cause the GSM symptoms of vaginal dryness, itching, burning, frequent urinary tract infections and pain during sex. Replenishing the hormone through vaginal estrogen is an effective GSM treatment. But many breast cancer survivors either can’t or don’t want to use estrogen.
AI mammogram readings are already helping doctors detect breast cancerAI mammogram readings are already helping doctors detect breast cancer
When reading women’s routine mammograms, radiologists are increasingly augmenting what they’re observing with artificial intelligence to better interpret the scan.
Scientists develop one-product-fits-all immunotherapy for breast cancerScientists develop one-product-fits-all immunotherapy for breast cancer
Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful therapies.
How to lower your risk of breast cancerHow to lower your risk of breast cancer
About 1 in 8 women in the U.S. will have breast cancer in their lifetime, making it the most common cancer among women. So you might wonder: Is there anything you can do to prevent it?
New AI Tool Can Predict Breast Cancer RiskNew AI Tool Can Predict Breast Cancer Risk
A new artificial intelligence model called Clairity Breast is being used to predict a woman’s risk of developing breast cancer by using the information hidden inside a standard mammogram. In studies, Clairity’s predictions were roughly 30% more accurate than traditional risk models which rely on family and personal health history. NBC’s Savannah Sellers reports for TODAY.
GLP-1 drugs help protect against sleep apnea, study saysGLP-1 drugs help protect against sleep apnea, study says
Weight-loss drugs like Ozempic and Zepbound might help protect people from health risks related to sleep apnea, a new study says. Weight-loss drugs like Ozempic and Zepbound might help protect people from health risks related to sleep apnea, a new study says.
GLP-1 Drugs Tied to Lower Risk of Legal Blindness in People With DiabetesGLP-1 Drugs Tied to Lower Risk of Legal Blindness in People With Diabetes
(MedPage Today) — ORLANDO — Adding another twist to the ongoing debate about the effects of weight-loss drugs on vision, a retrospective cohort study linked GLP-1 receptor agonists to a lower risk of legal blindness in patients with type 2… (MedPage Today) — ORLANDO — Adding another twist to the ongoing debate about the Read More
Breast cancer protein discovery could restore hormone therapy responseBreast cancer protein discovery could restore hormone therapy response
Know someone who’s been diagnosed with breast cancer? There’s a good chance that person has received hormone therapy. Estrogen receptor-positive (ER+) breast cancers account for about 75% of cases. Hormone therapy is one of the most common and effective treatments. However, it’s far from a cure.
OTC CGM at Walmart; California’s Own Insulin; Ozempic’s Price Negotiations UnderwayOTC CGM at Walmart; California’s Own Insulin; Ozempic’s Price Negotiations Underway
(MedPage Today) — Walmart will be the first physical U.S. retailer to carry Abbott’s over-the-counter (OTC) continuous glucose monitor (CGM). (Axios) Very few U.S. adults have heard of cardiovascular-kidney-metabolic syndrome despite almost 90… (MedPage Today) — Walmart will be the first physical U.S. retailer to carry Abbott’s over-the-counter (OTC) continuous glucose monitor (CGM). (Axios) Read More
AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrenceAI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence
Breast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year, and continues to be one of the main causes of cancer-related mortality. Precisely predicting whether this type of tumor will reappear remains one of the key challenges in oncology.